Mechanism of capmatinib degradation in stress conditions including degradation product characterization using ultra‐high‐performance liquid chromatography‐quadrupole‐time of flight mass spectrometry and stability‐indicating analytical method development

Rationale Capmatinib (CMT) has been recently approved for the treatment of non‐small cell lung cancer by the United States Food and Drug Administration (USFDA). Till date, the degradation mechanism of CMT in different stress conditions is not known. Moreover, degradation products (DPs) of the drug a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rapid communications in mass spectrometry 2023-01, Vol.37 (1), p.e9417-n/a
Hauptverfasser: Bhangare, Dhiraj, Rajput, Niraj, Jadav, Tarang, Sahu, Amit Kumar, Sengupta, Pinaki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Rationale Capmatinib (CMT) has been recently approved for the treatment of non‐small cell lung cancer by the United States Food and Drug Administration (USFDA). Till date, the degradation mechanism of CMT in different stress conditions is not known. Moreover, degradation products (DPs) of the drug are yet to be identified. Characterization study on degradation products of CMT has not been reported before. Furthermore, no previously reported literature is available on the stability‐indicating method of CMT. Methods Owing to the lack of such scientific reports, we developed a sensitive, stability‐indicating method for CMT which can resolve it from all its degradation products. The method was validated as per the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH Q2 [R1]) guideline. We studied and established the degradation mechanism of CMT in different stress conditions. One degradation product (DP2) was isolated and characterized using 1H NMR. Results The degradation products (DP1, DP2 and DP3) of the drug have been identified and characterized for the first time by using high‐resolution mass spectrometry and 1H NMR spectroscopy. CMT was found to become degraded under acidic, basic and photolytic stress conditions in the solution phase to yield three major DPs. The drug was found to be stable in neutral hydrolysis, oxidation and thermal stress conditions. Conclusions DP1 was formed under acidic and basic hydrolytic conditions, whereas DP2 and DP3 were formed under photolytic conditions. Characterization of all the DPs has been carried out to establish their structures and understand the molecular mechanism behind the degradation of the drug. Few studies reported quantitative analysis of CMT and its metabolites in biological fluids. However, this is the first study to identify the unknown DPs of CMT and the mechanism of its degradation. Moreover, this article reports a stability‐indicating analytical method for CMT which has not yet been reported in any literature.
ISSN:0951-4198
1097-0231
DOI:10.1002/rcm.9417